Obalon Therapeutics, Inc. (OBLN): Price and Financial Metrics

Obalon Therapeutics, Inc. (OBLN)

Today's Latest Price: $1.02 USD

0.02 (1.50%)

Updated Jun 5 4:00pm

Add OBLN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

OBLN Stock Summary

  • With a year-over-year growth in debt of -88.64%, Obalon Therapeutics Inc's debt growth rate surpasses just 2.12% of about US stocks.
  • Revenue growth over the past 12 months for Obalon Therapeutics Inc comes in at -63.95%, a number that bests merely 2.53% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for OBLN comes in at -173.02% -- higher than that of only 2.53% of stocks in our set.
  • Stocks that are quantitatively similar to OBLN, based on their financial statements, market capitalization, and price volatility, are TUFN, ADMP, BGMD, RKDA, and FLDM.
  • Visit OBLN's SEC page to see the company's official filings. To visit the company's web site, go to www.obalon.com.
OBLN Daily Price Range
OBLN 52-Week Price Range

OBLN Stock Price Chart More Charts

OBLN Price/Volume Stats

Current price $1.02 52-week high $11.60
Prev. close $1.00 52-week low $0.62
Day low $0.99 Volume 198,573
Day high $1.05 Avg. volume 430,198
50-day MA $0.87 Dividend yield N/A
200-day MA $1.53 Market Cap 7.85M

Obalon Therapeutics, Inc. (OBLN) Company Bio

Obalon Therapeutics, a commercial-stage medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. The company was founded in 2008 and is based in Carlsbad, California.

OBLN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

OBLN Latest Social Stream

Loading social stream, please wait...

View Full OBLN Social Stream

Latest OBLN News From Around the Web

Below are the latest news stories about Obalon Therapeutics Inc that investors may wish to consider to help them evaluate OBLN as an investment opportunity.

Obalon Announces Further Impacts Related To Covid-19 Crisis and Current Business Environment

Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces changes related to the impacts of the Covid-19 crisis and current business environment on its business, organization and strategic options. As previously announced, the overall uncertainty, the restriction on elective procedures and the specific directives issued by the Governor of California as a result of Covid-19 have had a significant impact on Obalon’s business. In March, the Company halted sales to new patients in its company-branded retail treatment centers and expansion plans for additional retail centers, which was pa...

Yahoo | May 11, 2020

William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as Director

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic, the Company’s President and CEO has announced his resignation in order to accept another position. To assist the Company in the transition, Mr. Plovanic has agreed to remain as President and CEO through completion and filing of Obalon’s Form 10-Q for the quarter ended March 31, 2020 (the “Quarterly Report”).

Yahoo | May 8, 2020

Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric Balloons

Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity provided further clarification that it’s gas-filled balloon is not the subject of the April 27, 2020 letter issued by the FDA to health care providers warning of serious potential risks, including deaths, associated with the use of liquid-filled intragastric balloons. The Obalon swallowable, gas-filled balloon system utilizes a very different design and technology than the liquid-filled balloons cited now in four FDA letters to health care providers.

Yahoo | April 28, 2020

The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutic...

Benzinga | April 7, 2020

Obalon Therapeutics explores strategic alternatives as coronavirus hits

Alternatives may include equity or debt financing, sale of the company, business combination, merger or reverse merger with another party, the company said. The COVID-19 crisis has significantly impacted Obalon’s stock price and its ability to access additional capital, the company added.

Yahoo | March 25, 2020

Read More 'OBLN' Stories Here

OBLN Price Returns

1-mo 14.61%
3-mo -9.73%
6-mo -41.38%
1-year -90.29%
3-year -98.98%
5-year N/A
YTD -46.32%
2019 -90.82%
2018 -68.68%
2017 -25.31%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8094 seconds.